214 related articles for article (PubMed ID: 37267484)
1. Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Nursing Care.
Cazeau N; Rodriguez S
Clin J Oncol Nurs; 2023 May; 27(3):259-265. PubMed ID: 37267484
[TBL] [Abstract][Full Text] [Related]
2. Treatment and Nursing for Steroid-Refractory Acute Graft-Versus-Host Disease.
Cazeau N; Rodriguez SL
Clin J Oncol Nurs; 2023 Jul; 27(4):397-403. PubMed ID: 37677777
[TBL] [Abstract][Full Text] [Related]
3. Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
Spałek A; Grygoruk-Wiśniowska I; Gruenpeter K; Panz-Klapuch M; Helbig G
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556924
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis.
Oyama T; Matsuda K; Honda A; Maki H; Masamoto Y; Murakami D; Toya T; Sakurai M; Kataoka K; Doki N; Kurokawa M
Int J Hematol; 2023 Feb; 117(2):260-268. PubMed ID: 36251231
[TBL] [Abstract][Full Text] [Related]
5. Low-dose rituximab in steroid-refractory chronic graft-versus-host disease.
Colunga-Pedraza PR; Barbosa-Castillo LM; Coronado-Alejandro EU; Vaquera-Alfaro HA; López-Reyna IG; Colunga-Pedraza JE; Gómez-Almaguer D
Transpl Immunol; 2023 Dec; 81():101959. PubMed ID: 37972876
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
[TBL] [Abstract][Full Text] [Related]
7. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH
Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202
[TBL] [Abstract][Full Text] [Related]
8. [Recent advances in prevention and treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
Toubai T; Hosokawa Y
Rinsho Ketsueki; 2024; 65(5):401-411. PubMed ID: 38825520
[TBL] [Abstract][Full Text] [Related]
9. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
Front Immunol; 2021; 12():673636. PubMed ID: 34276662
[TBL] [Abstract][Full Text] [Related]
10. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.
Wolff D; Fatobene G; Rocha V; Kröger N; Flowers ME
Bone Marrow Transplant; 2021 Sep; 56(9):2079-2087. PubMed ID: 34218265
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
Koshy AG; Kim HT; Liegel J; Arnason J; Ho VT; Antin JH; Joyce R; Cutler C; Gooptu M; Nikiforow S; Logan EK; Elavalakanar P; Narcis M; Stroopinsky D; Avigan ZM; Boussi L; Stephenson S; El Banna H; Bindal P; Cheloni G; Avigan DE; Soiffer RJ; Rosenblatt J
Blood; 2023 Jun; 141(24):2932-2943. PubMed ID: 36862975
[TBL] [Abstract][Full Text] [Related]
13. Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development.
Kim DDH; Popradi G; Lepic K; Paulson K; Allan D; Nampoothiri RV; Lachance S; Deotare U; White J; Elemary M; Jamani K; Fraga C; Lemieux C; Novitzky-Basso I; Law AD; Kumar R; Walker I; Schultz KR;
Curr Oncol; 2024 Mar; 31(3):1426-1444. PubMed ID: 38534941
[TBL] [Abstract][Full Text] [Related]
14. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Gonzalez RM; Pidala J
Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
Belina ME; Driscoll TA; Blanchard SK; Cardones AR
Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
[TBL] [Abstract][Full Text] [Related]
16. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
[TBL] [Abstract][Full Text] [Related]
17. ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.
Hamad N; Bilmon I; Chee L; Henden A; Johnston A; Purtill D; Bajel A; Tey SK; Yeung D; Cole T; Lewis C; Butler J
Intern Med J; 2023 Dec; 53(12):2319-2329. PubMed ID: 38014511
[TBL] [Abstract][Full Text] [Related]
18. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S
Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France.
Michonneau D; Quignot N; Jiang H; Reichenbach D; Kelly M; Burrell A; Zhang X; Thiruvillakkat K; Mohty M
Bone Marrow Transplant; 2023 May; 58(5):514-525. PubMed ID: 36765178
[TBL] [Abstract][Full Text] [Related]
20. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
